Transient Paraproteinemia: An Intriguing Immunological Anomaly

Size: px
Start display at page:

Download "Transient Paraproteinemia: An Intriguing Immunological Anomaly"

Transcription

1 Annals of Clinical & Laboratory Science, vol. 33, no. 3, Transient Paraproteinemia: An Intriguing Immunological Anomaly Stephen L. Strobel Department of Pathology, St. Vincent Mercy Medical Center, Toledo, Ohio Abstract. Serum transient paraproteins are small monoclonal immunoglobulins that are induced by a selflimiting regulatory defect in the control of certain terminally differentiated B-cell clones. Relatively uncommon and ill-defined in the medical literature, such proteins may be regarded as immunologic anomalies. Their clinical significance and potential impact on patient management are poorly understood. To elucidate this phenomenon, we reviewed the serum transient paraproteins that were encountered in a large community hospital during a 12 mo period. Twelve transient paraproteins were identified in a total of 895 serum protein electrophoreses reviewed (1.3% incidence). The relationships of the transient paraproteins to specific diseases were studied. (received 4 March 2003; accepted 27 March 2003) Keywords: transient paraprotein, electrophoresis, immunofixation, monoclonal protein, autoimmunity Introduction Serum protein electrophoresis (SPE) is a diagnostic laboratory test that separates and quantifies several classes of serum proteins and that identifies and characterizes the monoclonal gammopathies (Mproteins). M-proteins are indicative of certain lymphoproliferative conditions, eg, multiple myeloma and Waldenström s macroglobulinemia [1-3]. Serial monitoring of SPE M-protein concentrations is used to evaluate therapeutic responses and disease progression. The widespread use of SPE has revealed a low incidence of potential precursors to lymphoproliferative neoplasia, termed monoclonal gammopathies of undetermined significance (MGUS), most often seen in older adults. In a recent study by Kyle et al [4], the risk of MGUS progressing to multiple myeloma and related disorders was approximately 1% per year. The clinical utility of SPE extends beyond the monoclonal gammopathies. Alterations in the concentrations of certain protein fractions are typical of various pathological conditions. For example, the acute phase reaction (decreased albumin and transferrin fractions, elevated alpha-1 and alpha-2 globulin fractions) is indicative of an acute Address correspondence to Stephen L. Strobel, M.D., Department of Pathology, St. Vincent Mercy Medical Center, 2213 Cherry Street, Toledo, OH , USA; tel ; fax ; stephen_strobel@mhsnr.orrg. inflammatory process. Diffuse (polyclonal) hypergammaglobulinemia is associated with chronic inflammatory disorders, including chronic liver, collagen vascular, and granulomatous diseases. Hypogammaglobulinemia is observed with immune deficiencies, lymphoproliferative neoplasia, and with cytotoxic or immunosuppressive drug therapy. Specific, isolated protein abnormalities, such as alpha-1 antitrypsin deficiency, IgA deficiency, and hyperbetalipoproteinemia may be initially suggested by an abnormal SPE pattern [5]. Occasional SPE patterns contain transient protein bands of uncertain clinical significance. When evaluated further with immunofixation electrophoresis (IFE), many of these prove to be pseudoparaproteins, such as C-reactive protein or fibrinogen [6]. A minority, however, are true transient M-proteins. Of esoteric etiology, these transient paraproteins (TP) pose diagnostic dilemmas to clinical scientists and physicians. To examine our experience with serum TP, all SPE patterns produced during a 12 mo period were reviewed. TP were defined as small monoclonal immunoglobulins identified in an initial SPE pattern, confirmed by IFE, and absent in follow-up SPE patterns on at least two distinct occasions. Twelve TP were identified in a total of 895 SPE patterns that were reviewed. The major diseases of the 12 patients with TP were tabulated in an attempt to deduce potential relationships /03/0300/0265 $ by the Association of Clinical Scientists, Inc.

2 266 Annals of Clinical & Laboratory Science Methods and Materials Transient paraproteins (TP) were defined as monoclonal immunoglobulins detected by routine SPE during an initial patient evaluation, but absent in follow-up studies on at least 2 occasions (Fig. 1). Patients with serum TP were followed for at least 6 mo and a maximum (thus far) of 2 yr, with an average follow-up of 18 mo. All TP were confirmed and characterized with serum IFE. Follow-up (negative) SPE patterns for each patient were also correlated with serum IFE analysis to verify the absence of the paraprotein. All SPE and IFE were performed with the Paragon SPE-II Electrophoresis System (Beckman Instruments, Inc., Fullerton, CA). Serum samples were evaluated at standard dilutions according to the manufacturer s guidelines. A Beckman Appraise Densitometer was used to quantitate protein fractions. Antisera used for IFE were initially tested against normal controls to ensure the absence of reactivity against normally occurring proteins. Cerebrospinal fluid and urine protein electrophoresis patterns were not included in this study due to their small numbers. Results Twelve TP were identified in 895 SPE patterns from a total of 803 patients (age range 3 to 97 yr) produced durin a 12 mo period (January to December 2001). Of the TP, 10 were monoclonal and 2 were biclonal. Two separate follow-up SPE patterns were included in the study of each patient with an identified TP. The incidence and distribution of TP according to patient age and sex are compared to the entire study population in Fig. 2. Table 1 lists the 12 patients according to their age, sex, paraprotein subtype and concentration, and primary disease conditions. A total of 17 patients in the study had a primary diagnosis of an autoimmune disorder (systemic lupus erythematosus, rheumatoid arthritis, autoimmune hepatitis, or scleroderma), only 3 of which demonstrated serum TP. The TP identified in the serum of a patient with hepatitis C was a cryoglobulin. This was confirmed by identifying the IgM kappa band in the serum IFE performed at 37 C, with disappearance of this band when the serum sample was cooled to room temperature, centrifuged, and the IFE was repeated. Eleven patients with SPE patterns suggesting possible TP were lost to follow-up and hence were not included in the study. Discussion Transient paraproteins (TP) are an enigmatic laboratory phenomenon, inconsistently defined in the modern literature. Although technically a form of MGUS, these minor M-proteins are typically identified in the serum of patients with a spectrum of acute and chronic inflammatory illnesses. Whether these proteins imply an increased risk for plasma cell or lymphoid neoplasia has not been established. Their occurrence in the serum of some patients probably represents a self-limiting regulatory defect in the control of fully differentiated B-cell clones [7]. The evanescent nature of these serum proteins in the absence of specific immune suppression or anti-neoplastic therapy suggests that the most are benign. The SPE that contained TP were generally requested to evaluate a patient with an unexplained elevation of the serum total protein concentration, or an abnormal albumin:total protein ratio (implied hypergammaglobulinemia) that was detected by routine clinical chemistry studies. TP can easily be overlooked when hypergammaglobulinemia is present. Consequently, the true incidence of TP may be underestimated. Autoimmune diseases (ie, systemic lupus erythematosus, autoimmune hepatitis, and rheumatoid arthritis) were the primary diagnoses in 3 of the 12 patients with serum TP. Autoimmune disorders are manifestations of chronic activation of the immune system by undefined or poorly defined antigenic stimuli. Various pathogens, drugs, and toxins have been implicated as etiological agents [8-10]. A genetic predisposition is suspected in many cases. Due to hyperactivity of the immune system, individuals with autoimmune disorders may, in occasional cases, be predisposed to development of minor paraproteinemia, transient or persistent.

3 Transient paraproteinemia 267 Table 1. Age, sex, and major disease conditions associated with transient paraproteinemia in 12 patients. Gender Age Transient paraprotein 1 Associated major disease conditions (yr) (immunoglobulin type, g/dl) F 83 IgG lambda (0.1, 0.1) 2 Osteoarthritis (degenerative joint disease) M 48 IgM kappa (0.2) Guillain-Barré Syndrome F 47 IgM kappa (0.2) HCV 3 with cryoglobulinemia (type 2) M 54 IgG kappa (0.2, 0.1) 2 HCV 3 F 49 IgG kappa (0.1) Autoimmune hepatitis (ANA = 1:320) 4 F 69 IgG kappa (0.1) Coronary artery disease with previous cerebral vascular accident F 39 IgG kappa (0.2) Systemic lupus erythematosus 5 M 51 IgG kappa (0.1) Rheumatoid arthritis F 69 IgG kappa (0.2) Systemic lupus erythematosus with chronic renal failure 5 M 79 IgG kappa (0.2) Congestive heart failure M 68 IgG kappa (0.1) Sepsis, fever of unknown origin F 79 IgG kappa (0.1) Breast cancer (mastectomy 3 yr prior), clinical remission 1 Determined by serum immunofixation electrophoresis 2 Biclonal paraproteins 3 Hepatitis C infection (chronic hepatitis) 4 Anti-nuclear antibody titer 5 Bone marrow biopsy performed Fig. 1. Immunofixation electrophoresis (IFE) patterns demonstrating a typical transient paraprotein, IgG Lambda, and background polyclonal hypergammaglobulinemia (A), with disappearance of the transient paraprotein in the follow-up IFE performed 3 mo later (B).

4 268 Annals of Clinical & Laboratory Science Fig. 2. Distribution according to age and sex of 803 patients whose serum protein electrophoresis (SPE) patterns were reviewed. (The 12 patients with transient paraproteinemia are printed in parentheses at the top of the corresponding columns.) Serum paraproteins may be observed in patients with polyneuropathies and peripheral neuropathies [11-13]. The M-proteins may be otherwise subclinical (MGUS) or may be associated with clinically evident disease (eg, multiple myeloma, amyloidosis, lymphoma). The M-proteins and coexistent polyclonal antibodies may be directed against a variety of human peripheral nerve antigens, including myelin-associated glycoprotein (MAG) and anti-gm1 ganglioside [11]. In our series, the specificity of the transient paraprotein found in a patient with Guillain-Barré syndrome was not characterized, but a previous study has suggested an association with anti-gq1b IgG antibody [14]. The TP of one patient with chronic hepatitis C infection was a cryoglobulin. Cryoglobulins, immune complexes that precipitate (become insoluble) at temperatures below 37 C, are classified as types I, II, or III, depending on the nature of the immune complexes. Hepatitis C virus (HCV) infection is strongly associated with type II cryoglobulinemia [15-18]. The immune complexes of type II cryoglobulinemia typically consist of monoclonal IgM rheumatoid factor which reacts with polyclonal IgG. HCV virions are concentrated within the cryoglobulins of these patients. Type II cryoglobulinemia appears to be a manifestation of a lymphoplasmacytic disorder, which may be expressed as a multisystem inflammatory response

5 Transient paraproteinemia 269 to cryoglobulins or as a clinically overt malignant lymphoma [19]. An indolent phase of B-cell lymphoma may exist prior to clinical signs [20]. Bone marrow biopsies were performed to rule out plasma cell neoplasia in only two of our patients, one with chronic renal failure and the other with systemic lupus erythematosus. Both biopsies contained histologically normal populations of plasma cells and lymphocytes. Immunohistochemistry was used to confirm a normal kappa: lambda ratio in the plasma cells present in each biopsy. Flow cytometric immunophenotyping was not performed. TP must be distinguished from benign pseudoparaproteins, which are also transient and can mimic TP in routine SPE patterns [6]. Common serum pseudoparaproteins include hyperbetalipoproteinemia, fibrinogen, C-reactive protein, hemoglobinhaptoglobin complex (hemolyzed samples), and reactive increases of transferrin or complement C3. IFE is negative for each of these pseudoparaproteins. Quantitative measurement of the suspected pseudoparaprotein can be used to confirm its identity, if clinically relevant. Certain electrophoretic artifacts can be mistaken for TP [6]. Point-of-application artifact occurs as a thin, discrete line in the application well, and may be particularly prominent in samples containing immune complexes. Cathodal migration artifact may be observed in samples that have undergone prolonged electrophoretic migration (a technique related artifact). In both of these situations, as with pseudoparaproteins, the IFE is negative. For each of the TP identified in this study, the ordering physicians were contacted to determine their opinion regarding the laboratory findings, and whether or not their awareness of the TP influenced their patient management. Rheumatologists and hematologists/oncologists were inclined to view TP as aberrant benign reactive proteins in the serum. However, many clinicians suspected that these proteins could represent an early manifestation of a clandestine malignancy. Pathological/clinical correlation conferences provided an educational opportunity to define TP for clinicians and to emphasize that the TP was an appropriate reflection of a disease process, albeit of uncertain significance. No instance of TP recurrence was observed. However, the period of follow-up was too brief to conclude that the appearance of TP was necessarily an isolated event in the course of each patient s disease. Retrospective evaluation of SPE patterns performed in our laboratory prior to 2001 revealed that only 2 patients had previous SPE patterns analyzed, both of which were negative for paraprotein. This study is on-going, and all patients with TP detected in our laboratory are being monitored prospectively for recurrences. Acknowledgment The author thanks Ms Jill Woods for typing the manuscript, and Ms Shirley McGarity for technical assistance. References 1. Alexanian R, Weber D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med 1999;122: George ED, Sadovsky R. Multiple myeloma: recognition and management. Am Fam Phys 1999;59: Joliff CR. Classification and interpretation of Paragon serum protein electrophoresis patterns. Manual EP-1, Beckman Instruments, Brea, CA, 1991, pp Kyle Robert A, Therneau Terry M, Rajkumar Vincent S, Offord Janice R, Larson, Dirk R, Plevak, Matthrew F, Melton Joseph III. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346: Strobel SL. The significance of subtle alterations in routine serum protein electrophoresis patterns in one laboratory. Lab Med 2001;6: Strobel SL. The incidence and significance of pseudoparaproteins in a community hospital. Ann Clin Lab Sci 2000;30: Strobel ES, Fritschka E, Schmitt-Graff A, Peter HH. An unusual case of systemic lupus erythematosus, lupus nephritis, and transient monoclonal gammopathy. Rheumatol Int 2000;19: , 8. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J Clin Epidemiol 2002;55: Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol 2002;32 Suppl 1: Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4 Suppl 3:S

6 270 Annals of Clinical & Laboratory Science 11. Bosch EP, Smith BE. Peripheral neuropathies associated with monoclonal proteins. Med Clin North Amer 1993;77: Glass JD, Cornblath DR. Chronic inflammatory demyelinating polyneuropathy and paraproteinemic neuropathies. Curr Opin Neuro 1994;7: Nobile-Orazio E, Barbieri S, Baldini L, Marmiroli P, Carpo M, Premoselli S, Manfredini E, Scarlato G. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand 1992;85: Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-gq1b antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain- Barre syndrome: clinical and immunohistochemical studies. Neurology 1993;43: Agnello V, Chung RT, Lee MK. A role for hepatitis C infection in type II cryoglobulinemia. N Engl J Med 1992;327: Frangeul L, Musset L, Cresta P, Cacoub P, Huraux JM, Lunel F. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol 1996;25: Thomason R. Case study: Weakness of the extremities in a 40-year-old woman. Lab Med 2003;34: Mazzaro C, Franzin F, Tulissi P, Pussini E, Crovatto M, Carniello GS, Efremov DG, Burrone O, Santini G, Pozzato G. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 1996;77: Pozzato G, Mazzaro C, Crovatto M, Modolo ML, Ceselli S, Mazzi G, Sulfaro S, Franzin F, Tulissi P, Moretti M, etal. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994;84: Mussini C, Mascia MT, Zanni G, Curci G, Bonacorsi G, Artusi T. A cytomorphological and immunohistochemical study of bone marrow in the diagnosis of essential mixed type II cryoglobulinemia. Haematologica 1991;76:

What do you do, with an M protein?

What do you do, with an M protein? What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily

More information

Elevated Immunoglobulins and Paraproteins

Elevated Immunoglobulins and Paraproteins Elevated Immunoglobulins and Paraproteins NWL Pathology GP Study Afternoon Thursday 19 th October 2017 Dr Aristeidis Chaidos Consultant Haematologist and Honorary Senior Clinical Lecturer Hammersmith Hospital,

More information

The Incidence and Significance of Pseudoparaproteins in a Community Hospital

The Incidence and Significance of Pseudoparaproteins in a Community Hospital Annals o f Clinical & Laboratory Science, vol. 30, no. 3, 2000 289 The Incidence and Significance of Pseudoparaproteins in a Community Hospital Stephen Lewis Strobel Department of Pathology, St. Vincent

More information

This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed.

This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed. MGUS This Infosheet explains what Monoclonal Gammopathy of Undetermined Significance (MGUS) is and how it is diagnosed and managed. What is MGUS? Monoclonal gammopathy of undetermined significance, or

More information

Accuracy of Serum IgM and IgA Monoclonal Protein Measurements by Densitometry

Accuracy of Serum IgM and IgA Monoclonal Protein Measurements by Densitometry 160 Annals of Clinical & Laboratory Science, vol. 33, no. 2, 2003 Accuracy of Serum IgM and IgA Monoclonal Protein Measurements by Densitometry C. Howard Tseng, 1 Chin-Yung Chang, 2 Kevin S. Liu, 3 and

More information

+ Serum Protein Electrophoresis with Immunofixation

+ Serum Protein Electrophoresis with Immunofixation + Serum Protein Electrophoresis with Immunofixation Dr.Ajay Phadke Centre Head SRL Diagnostics-Dr.Avinash Phadke s Lab + What is electrophoresis? Electrophoresis is a method of separating proteins based

More information

Understanding MGUS and Smoldering Multiple Myeloma

Understanding MGUS and Smoldering Multiple Myeloma Multiple Myeloma Cancer of the Bone Marrow Understanding MGUS and Smoldering Multiple Myeloma u-mgus+smm_en_2017_i1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE

More information

Performance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins

Performance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins Immunopathology / SEBIA CAPILLARYS 2 PARAPROTEIN DETECTION Performance of the Sebia CAPILLARYS 2 for Detection and Immunotyping of Serum Monoclonal Paraproteins Zhaohai Yang, MD, PhD, Keith Harrison, MD,

More information

Anion Gap and Immunoglobulin Concentration

Anion Gap and Immunoglobulin Concentration Anion Gap and Immunoglobulin Concentration ALBERT A. KESHGEGIAN, M.D., PH.D. Keshgegian, Albert A.: Anion gap and immunoglobulin concentration. Am J Clin Pathol 74: 22-26,190. The serum anion gap is often

More information

Prevalence of Monoclonal Gammopathy of Undetermined Significance

Prevalence of Monoclonal Gammopathy of Undetermined Significance The new england journal of medicine original article Prevalence of Monoclonal Gammopathy of Undetermined Significance Robert A. Kyle, M.D., Terry M. Therneau, Ph.D., S. Vincent Rajkumar, M.D., Dirk R.

More information

Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples

Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples Immunopathology / Electrophoresis of Unconcentrated Urine Samples Urine Protein Electrophoresis and Immunoelectrophoresis Using Unconcentrated or Minimally Concentrated Urine Samples Anja C. Roden, MD,

More information

Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies

Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies Freelite for Measurement of Urine-Free Light Chains in Monoclonal Gammopathies Montgomery Lobe, MD, and Donald Pasquale, MD Abstract Monoclonal gammopathies are characterized by production of monoclonal

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL GENERAL FORMS AND GUIDELINES MYELOMA FORMS CHAPTER 16D REVISED: SEPTEMBER 2016

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL GENERAL FORMS AND GUIDELINES MYELOMA FORMS CHAPTER 16D REVISED: SEPTEMBER 2016 MYELOMA FORMS The guidelines and figures below are specific to Myeloma studies. The information in this manual does NOT represent a complete set of required forms for any myeloma study. Please refer to

More information

Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system

Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system Clinical Chemistry 44:5 944 949 (1998) Enzymes and Protein Markers Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system Xavier Bossuyt, * Ann Bogaerts, Gilberte Schiettekatte,

More information

Smouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:

Smouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline: Smouldering myeloma This Infosheet provides information on what smouldering myeloma is, how it is diagnosed, what the treatment is and will explain the link between smouldering myeloma and active myeloma.

More information

Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio

Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio Elmer ress Original Article J Clin Med Res. 2017;9(1):46-57 Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio Gurmukh

More information

Measuring Myeloma in the LAB. BL Ferry Clinical Lead Sept 15 th 2014

Measuring Myeloma in the LAB. BL Ferry Clinical Lead Sept 15 th 2014 Measuring Myeloma in the LAB BL Ferry Clinical Lead Sept 15 th 2014 Oxford Immunology Laboratory Clinical Immunology Churchill WHAT DO WE MEASURE AND HOW? Clinical Immunology Churchill Serum proteins Proteins

More information

Significance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation

Significance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation Original Article Significance of Abnormal Protein Bands in Patients with Multiple Myeloma following Autologous Stem Cell Transplantation Sara L. Hall, 1 Jill Tate, 2 Devinder Gill, 1,3 *Peter Mollee 1,3

More information

A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma

A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma 1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody

More information

SERUM PROTEIN ELECTROPHORESIS

SERUM PROTEIN ELECTROPHORESIS SERUM PROTEIN ELECTROPHORESIS ABD-ALLA BSC - OMDURMAN AHLIA HIGH DOPLOMA DGREE - ELZAEM EL-AZHARY FORMER HEAD OF HEMATOLOGY & BLOOD BANK MINISTRY OF HEALTH LABORATORY ADMINISTRATION KHARTOUM STATE MARKETING

More information

Nephelometry and turbidimetry are liquid based immunoassays based on the measurement of scattered or absorbed light.

Nephelometry and turbidimetry are liquid based immunoassays based on the measurement of scattered or absorbed light. 1 Nephelometry and turbidimetry are liquid based immunoassays based on the measurement of scattered or absorbed light. Light scattering is the physical phenomenon resulting from the interaction of light

More information

RESEARCH ARTICLE. Abstract. Introduction

RESEARCH ARTICLE. Abstract. Introduction RESEARCH ARTICLE The Immunotyping Distribution of Serum Monoclonal Paraprotein and Environmental Impact on Multiple Myeloma (MM) and Monoclonal Gammopathy of Uncertain Significance (MGUS) in Taiwan: A

More information

Immunoglobulin Database Report 2015/16

Immunoglobulin Database Report 2015/16 Immunoglobulin Database Report 2015/16 1 Database Overview Rob Hollingsworth CHAPTER 1 Introduction I would firstly like to thank all Trusts and their staff that continue to support and provide data to

More information

Biotest AG. Jefferies Healthcare Conference New York, June 7-10, 2016

Biotest AG. Jefferies Healthcare Conference New York, June 7-10, 2016 . Jefferies Healthcare Conference New York, June 7-10, 2016 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial

More information

2. Relay characteristics of proteins and protein electrophoresis / fractionation.

2. Relay characteristics of proteins and protein electrophoresis / fractionation. UNIT: Proteins 15prot_elec.wpd Task Electrophoresis Objectives Upon completion of this exercise, the student will be able to: 1. Review electrophoresis information as presented in class. 2. Relay characteristics

More information

Capillary Zone Electrophoresis in the Evaluation of Serum Protein Abnormalities

Capillary Zone Electrophoresis in the Evaluation of Serum Protein Abnormalities Capillary Zone Electrophoresis in the Evaluation of Serum Protein Abnormalities David F. Keren, MD Key Words: Capillary zone electrophoresis; M-protein; Serum protein electrophoresis; monoclonal gammopathy;

More information

A Study of Serum Protein Electrophoresis in Patients with Multiple Myeloma

A Study of Serum Protein Electrophoresis in Patients with Multiple Myeloma MULTIPLE THE IRAQI POSTGRADUATE MYELOMA MEDICAL JOURNAL A Study of Serum Protein Electrophoresis in Patients with Multiple Myeloma Hind Shakir Ahmed ABSTRACT: BACKGROUND: Multiple myeloma (MM) is caused

More information

Myeloma Primary Care. Dr R Lovell Feb 2015

Myeloma Primary Care. Dr R Lovell Feb 2015 Myeloma Primary Care Dr R Lovell Feb 2015 Aims Balance of pathophysiology and cases Explain diagnostic changes (minimal) Staging UK influence Autologous stem cell transplants Primary care myeloma problems

More information

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects

More information

Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells

Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells Hematopathology / Flow Cytometric Analysis of Clonal Plasma Cells Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells Derek K. Marsee,

More information

Human Rheumatoid Factor IgM ELISA Kit

Human Rheumatoid Factor IgM ELISA Kit Product Manual Human Rheumatoid Factor IgM ELISA Kit Catalog Number PRB- 5066 PRB- 5066 96 assays 5 x 96 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Rheumatoid arthritis

More information

NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35

NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35 Myeloma: diagnosis and management NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Management of Multiple Myeloma: The Changing Paradigm

Management of Multiple Myeloma: The Changing Paradigm Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Hans Lee, MD Assistant Professor Department of Lymphoma/Myeloma University of Texas MD Anderson Cancer Center No Disclosures

More information

Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line

Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY

More information

AAG PRINCIPLE SPECIMEN. REF (150 tests) ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE

AAG PRINCIPLE SPECIMEN. REF (150 tests) ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE IMMAGE Immunochemistry Systems Chemistry Information Sheet Copyright 2010 Beckman Coulter, Inc. Alpha 1 -Acid Glycoprotein REF 447780 (150 tests) For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by:

More information

CHAPTER 3 ANTIBODY STRUCTURE I

CHAPTER 3 ANTIBODY STRUCTURE I CHAPTER 3 ANTIBODY STRUCTURE I See APPENDIX: (3) OUCHTERLONY ANALYSIS; (6), EQUILIBRIUM DIALYSIS; (7) CROSS-REACTIVITY Electrophoretic separation of serum proteins identifies the GAMMA-GLOBULIN fraction

More information

Diagnosis and staging

Diagnosis and staging Chapter 2 Diagnosis and staging Carlos Fernández de Larrea and Joan Bladé Diagnostic criteria Multiple myeloma (MM) is a plasma cell disorder characterized by a clonal proliferation of cells producing

More information

LECTURE: 26 SIMPLE SEROLOGICAL LABORATORY TECHNIQUES LEARNING OBJECTIVES:

LECTURE: 26 SIMPLE SEROLOGICAL LABORATORY TECHNIQUES LEARNING OBJECTIVES: LECTURE: 26 Title SIMPLE SEROLOGICAL LABORATORY TECHNIQUES LEARNING OBJECTIVES: The student should be able to: Define the term "simple serological techniques". Describe the benefit of the use of serological

More information

THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org

THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters

More information

DTT Treated Reagent Red Cells for use in Resolving DARA Interference. More Than Just Kell?? Marilyn Stewart MT(ASCP)SBB

DTT Treated Reagent Red Cells for use in Resolving DARA Interference. More Than Just Kell?? Marilyn Stewart MT(ASCP)SBB DTT Treated Reagent Red Cells for use in Resolving DARA Interference More Than Just Kell?? Marilyn Stewart MT(ASCP)SBB Daratumumab Anti-myeloma and anti-lymphoma agent known to interfere with routine Blood

More information

Flow Cytometry in the Diagnosis of Hematopoietic Neoplasia. Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle

Flow Cytometry in the Diagnosis of Hematopoietic Neoplasia. Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle Flow Cytometry in the Diagnosis of Hematopoietic Neoplasia Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle 1 Flow Cytometer 2 The Power of Flow Cytometry Single cell

More information

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) 1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous

More information

Multiple Myeloma Patient Handbook

Multiple Myeloma Patient Handbook Myeloma Canada Mailing Address: Myeloma Canada 1255 Trans-Canada Highway Suite 160 Dorval, QC H9P 2V4 Telephone: Toll-free: 1-888-798-5771 E-mail: contact@myeloma.ca Multiple Myeloma Patient Handbook Website:

More information

Immunotherapy in myeloma

Immunotherapy in myeloma Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to

More information

Introduction.-Sera from patients with systemic lupus erythematosus often

Introduction.-Sera from patients with systemic lupus erythematosus often ANTIBODIES TO RIBONUCLEIC ACID IN SYSTEMIC LUPUS ERYTHEMATOSUS* BY PETER H. SCHUR AND MARGARET MONROE DEPARTMENT OF MEDICINE, ROBERT B. BRIGHAM HOSPITAL, HARVARD MEDICAL SCHOOL Communicated by Albert H.

More information

CHEMILUMINESCENCE ENZYME IMMUNOASSAY (CLIA) THYROID STIMULATING HORMONE (FERRITIN) Ferritin

CHEMILUMINESCENCE ENZYME IMMUNOASSAY (CLIA) THYROID STIMULATING HORMONE (FERRITIN) Ferritin DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and 116, Woodland hills CA 91367 USA Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com

More information

Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.

Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects. Heparin Induced Eric Kraut, MD Professor of Internal Medicine The Ohio State University Medical Center Heparin Induced Heparin induced thrombocytopenia occurs in up to 5 % of patients receiving unfractionated

More information

Measurement of immune complexes is not useful in routine clinical practice

Measurement of immune complexes is not useful in routine clinical practice Review Article Ann Clin Biochem 2000; 37: 253±261 Measurement of immune complexes is not useful in routine clinical practice R J Lock and D J Unsworth From the Department of Immunology, Southmead Hospital,

More information

Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey

Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey VOLUME 8 NUMBER 3 September 2017 JOURNAL OF CLINICAL AND EXPERIMENTAL INVESTIGATIONS ORIGINAL ARTICLE Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing

More information

Anti-Cardiolipin IgG/IgM Enzyme Immunoassay

Anti-Cardiolipin IgG/IgM Enzyme Immunoassay For Individual Laboratory to Complete: Laboratory Name Anti-Cardiolipin IgG/IgM Enzyme Immunoassay Adopted Reviewed Reviewed Revised Supercedes Method: Diamedix Corp., Immunosimplicity Manual or in conjunction

More information

Introduction. Point. Keywords: electrophoresis; Hevylite; IgA; immunoglobulin; monoclonal protein.

Introduction. Point. Keywords: electrophoresis; Hevylite; IgA; immunoglobulin; monoclonal protein. Clin Chem Lab Med 2015; aop Point Josie A.R. Evans*, Ellen L. Jenner, Hugh D. Carr Smith, Oscar Berlanga and Stephen J. Harding Quantification of β-region IgA monoclonal proteins shouldwe include immunochemical

More information

Serum protein electrophoresis: Italian survey 1986

Serum protein electrophoresis: Italian survey 1986 Ann Clin Biochem 1989; 26: 249-253 Serum protein electrophoresis: Italian survey 1986 F AGUZZI, C PETRINI'" and C GASPARRO From the Laboratorio Analisi Ospedali di Broni e Stradel/a, Pavia, and " Laboratorio

More information

Mechanisms of extravascular destruction of red cells coated with IgG1 or IgG3 (± C3b).

Mechanisms of extravascular destruction of red cells coated with IgG1 or IgG3 (± C3b). Introduction - Antibodies involved in transfusion reactions are of two types, namely the complete and the incomplete. - whereas the complete antibodies agglutinate red cells in saline medium, the incomplete

More information

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) 23 July 2015 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular

More information

Myeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation

Myeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation Myeloma Bone Disease Current and Future Treatment A Publication of The Bone and Cancer Foundation What Is Multiple Myeloma? Multiple Myeloma is a cancer that results from a malignant change in a particular

More information

Biomarkers: Physiological & Laboratory Markers of Drug Effect

Biomarkers: Physiological & Laboratory Markers of Drug Effect Biomarkers: Physiological & Laboratory Markers of Drug Effect Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration January 23, 2014 1 Why Are Biomarkers Important?

More information

Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels

Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels Published Ahead of Print on February 1, 2018, as doi:10.3324/haematol.2017.184226. Copyright 2018 Ferrata Storti Foundation. Cytogenetic aberrations in multiple myeloma are associated with shifts in serum

More information

Right and wrong in antinuclear antibody tests. Timo Walle HUSLAB, Department of Immunology

Right and wrong in antinuclear antibody tests. Timo Walle HUSLAB, Department of Immunology Right and wrong in antinuclear antibody tests Timo Walle HUSLAB, Department of Immunology Antinuclear antibodies (ANA) Autoantibodies reacting with nuclear antigens Nucleoplasm Nuclear membrane Nucleoli

More information

Polyclonal versus monoclonal immunoglobulin-free light chains quantification

Polyclonal versus monoclonal immunoglobulin-free light chains quantification Original Article Annals of Clinical Biochemistry 2015, Vol. 52(3) 327 336! The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563214553808 acb.sagepub.com

More information

The clinical utility of IPF in thrombocytopenia

The clinical utility of IPF in thrombocytopenia The clinical utility of IPF in thrombocytopenia Platelets platelets Platelets are the smallest blood cells which are released by cytoplasmic blebbing of megakaryocytes with an average size of 2um. Normal

More information

FER PRINCIPLE SPECIMEN. REF (150 tests) ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE

FER PRINCIPLE SPECIMEN. REF (150 tests) ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE IMMAGE Immunochemistry Systems Chemistry Information Sheet Copyright 2010 Beckman Coulter, Inc. Ferritin REF 447160 (150 tests) For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by: Date Reviewed by:

More information

Immunoglobulins: Structure and Function

Immunoglobulins: Structure and Function Immunoglobulins: Structure and Function Immunoglobulins:Structure and Function Definition: Glycoprotein molecules that are produced by plasma cells in response to an immunogen and which function as antibodies

More information

Transgender Fundamentals for Health Care Practitioners Course # / 1.0 credit hours

Transgender Fundamentals for Health Care Practitioners Course # / 1.0 credit hours Transgender 101 - Fundamentals for Health Care Practitioners Course # 612-405-17 / 1.0 credit hours Paula Neira, JD, MSN, RN, CEN Clinical Program Director Center for Transgender Health Johns Hopkins Health

More information

Assays for Immunogenicity: Are We There Yet?

Assays for Immunogenicity: Are We There Yet? Assays for Immunogenicity: Are We There Yet? Mark Wener, MD Department of Laboratory Medicine & Rheumatology Division Department of Medicine University of Washington Seattle, WA 98195 wener@uw.edu Goals:

More information

Your Test Results. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow

Your Test Results. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow Multiple Myeloma Cancer of the Bone Marrow Understanding Your Test Results u-ytr_en_2017_h4 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada)

More information

immuno concepts Immuno Concepts is proud to announce that when present the characteristic SS-A/Ro pattern detected by the HEp-2000 substrate

immuno concepts Immuno Concepts is proud to announce that when present the characteristic SS-A/Ro pattern detected by the HEp-2000 substrate immuno concepts Immuno Concepts is proud to announce that when present the characteristic SS-A/Ro pattern detected by the HEp-2000 substrate is now considered confirmatory for the presence of antibodies

More information

Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg)

Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) 1 2 3 15 December 2016 EMA/CHMP/BPWP/94033/2007 rev. 3 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on the clinical investigation of human normal immunoglobulin for intravenous

More information

Serology as a Diagnostic Technique

Serology as a Diagnostic Technique Serology as a Diagnostic Technique Characteristics of Any Diagnostic Techniques Any useful detection strategy must be: Specific: yield a positive response for only the target organism or molecule. Sensitive:

More information

Prothrombin (Factor II) IgG ELISA

Prothrombin (Factor II) IgG ELISA Prothrombin (Factor II) IgG ELISA Quantitative assay for anti-prothrombin IgG antibodies For Research Use Only. Not For Use In Diagnostic Procedures. Updates from previous version: 09/03 are non-critical

More information

To learn more about the MMRF, visit or call Accredited by: 2015 Multiple Myeloma Reseach Foundation

To learn more about the MMRF, visit  or call Accredited by: 2015 Multiple Myeloma Reseach Foundation ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION Shortly after being diagnosed with multiple myeloma, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF in 1998

More information

Advanced Therapies for the Immune Compromised

Advanced Therapies for the Immune Compromised Advanced Therapies for the Immune Compromised CORPORATE OVERVIEW SEPTEMBER 2015 1 WWW.ADMABIOLOGICS.COM FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking statements", pursuant to the

More information

Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry

Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry Clinical proteomics is the application of proteomic approach to the field of medicine. Proteome of an organism changes

More information

An indirect haemagglutination test to detect serum antibodies to Giardia lamblia

An indirect haemagglutination test to detect serum antibodies to Giardia lamblia J. Biosci., Vol. 10, Number 4, December 1986, pp. 475-480. Printed in India. An indirect haemagglutination test to detect serum antibodies to Giardia lamblia K. N. JALAN, TUSHER MAITRA and RITA DAS Kothari

More information

Blood Typing Monoclonal Antibodies. Blood typing intermediates for further manufacturing use

Blood Typing Monoclonal Antibodies. Blood typing intermediates for further manufacturing use Blood Typing Monoclonal Antibodies Blood typing intermediates for further manufacturing use Merck Millipore, your partner for monoclonal blood typing antibodies For more than 25 years we have been leading

More information

Immunological quantitation of IgG and IgM in milk and serum of the goat at different stages of the reproductive cycle

Immunological quantitation of IgG and IgM in milk and serum of the goat at different stages of the reproductive cycle Available online at www.scholarsresearchlibrary.com Scholars Research Library Annals of Biological Research, 2015, 6 (9):16-20 (http://scholarsresearchlibrary.com/archive.html) ISSN 0976-1233 CODEN (USA):

More information

CHAPTER 5 COMPLEMENT

CHAPTER 5 COMPLEMENT CHAPTER 5 COMPLEMENT See APPENDIX (8) COMPLEMENT FIXATION ASSAY The complex of serum proteins known as COMPLEMENT plays key roles in the lytic and inflammatory properties of antibodies. The CLASSICAL pathway

More information

The Science of Monoclonal Antibody Therapy: Introducing Canine Atopic Dermatitis Immunotherapeutic*

The Science of Monoclonal Antibody Therapy: Introducing Canine Atopic Dermatitis Immunotherapeutic* The Science of Monoclonal Antibody Therapy: Introducing Canine Atopic Dermatitis Immunotherapeutic* *This product license is conditional. Efficacy and potency test studies are in progress. Michele Rosenbaum,

More information

FINAL DOCUMENT. Global Harmonization Task Force. Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts

FINAL DOCUMENT. Global Harmonization Task Force. Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts GHTF/SG5/N6:2012 FINAL DOCUMENT Global Harmonization Task Force Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts Authoring Group: Study Group 5 of the Global Harmonization

More information

Biotechnology of Human Plasma-Derived Medicines in Scope of Collaboration Perspectives within The Central European Initiative

Biotechnology of Human Plasma-Derived Medicines in Scope of Collaboration Perspectives within The Central European Initiative Biotechnology of Human Plasma-Derived Medicines in Scope of Collaboration Perspectives within The Central European Initiative Dr Vadim Sentchouk PHARMLAND LLC Deputy General Director PLASMAPHARM LLC General

More information

Ebola Facts. October 14, 2014

Ebola Facts. October 14, 2014 Ebola Facts October 14, 2014 Symptoms of Ebola Initial symptoms are nonspecific - may include fever, chills, myalgias, and malaise. Patients can progress to develop gastrointestinal symptoms: severe watery

More information

Ed Harris - Background (Revised 1/25/16)

Ed Harris - Background (Revised 1/25/16) Ed Harris - Background (Revised 1/25/16) Contact: eharris@sclerodermainfo.org Personal, Professional, and Academic Background Age: 68, currently retired Academic background: o BS Mathematics 1967 o MS

More information

Hot Topic. Disclosures. None

Hot Topic. Disclosures. None Hot Topic Multiple Myeloma Testing at Mayo Medical Laboratories HOT TOPIC / 2017 MFMER 1 Our speaker for this program is Dragan Jevremovic, MD, PhD Assistant Professor, Division of Hematopathology at Mayo

More information

Guidelines for the diagnosis and management of Myeloma within AngCN

Guidelines for the diagnosis and management of Myeloma within AngCN Guidelines for the diagnosis and management of Myeloma within AngCN Ref: AngCN-SSG-Ha5 Cancer Standards Measure: N/A Page 1 of 11 Approved and Published: March 2013 1 Introduction These brief guidelines

More information

Myeloma treatment algorithm 1999

Myeloma treatment algorithm 1999 Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham

More information

PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec)

PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec) PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec) INDICATION IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable

More information

Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.

Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse. Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham

More information

Mechanisms of Action of Anti-GM 1 and Anti-GQ 1b Ganglioside Antibodies in Guillain-Barré Syndrome

Mechanisms of Action of Anti-GM 1 and Anti-GQ 1b Ganglioside Antibodies in Guillain-Barré Syndrome S144 Mechanisms of Action of Anti-GM 1 and Anti-GQ 1b Ganglioside Antibodies in Guillain-Barré Syndrome Hugh J. Willison, Graham O Hanlon, Gary Paterson, Colin P. O Leary, Jean Veitch, George Wilson, Mark

More information

IG Production and Safety

IG Production and Safety IG Production and Safety Platelet Disorder Support Association July 20, 2013 Mary Gustafson, Vice President, PPTA Global Regulatory Policy Presentation Outline Introduction - PPTA Plasma Collection Final

More information

PeliClass human IgG subclass ELISA kit Enzyme-linked immunosorbent assay

PeliClass human IgG subclass ELISA kit Enzyme-linked immunosorbent assay PeliClass human IgG subclass ELISA kit Enzyme-linked immunosorbent assay Catalog No: M1551 Size: six pre-coated 8-well strips for each of the four IgG subclasses Test description The PeliClass human subclass

More information

Step-by-Step Description of ELISA

Step-by-Step Description of ELISA Step-by-Step Description of ELISA The protocols in this kit rely on indirect antibody capture ELISA. The steps in this assay are: Step 1: Antigen is added to the wells of the microplate strip and incubated

More information

LYMPHOPROLIFERATIVE. ALL- Acute Lymphoblastic leukemia. Non Hodgkin Lymphomas. Hodgkin Lymphomas. CLL-Chronic Lymphocytic Leukemia

LYMPHOPROLIFERATIVE. ALL- Acute Lymphoblastic leukemia. Non Hodgkin Lymphomas. Hodgkin Lymphomas. CLL-Chronic Lymphocytic Leukemia של בדיקת Free Light Chains מקומה באבחון ומעקב של מיאלומה נפוצה ד"ר תמר תדמור מכון המטולוגי, בני ציון הקבוצה הישראלית למיאלומה נפוצה LYMPHOPROLIFERATIVE DISEASES ALL- Acute Lymphoblastic leukemia Non Hodgkin

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing

More information

MOSAIQUES DIAGNOSTICS

MOSAIQUES DIAGNOSTICS MOSAIQUES DIAGNOSTICS CLINICAL PROTEOMICS IN DRUG DEVELOPMENT INFORMATION Clinical Proteomics for early and differential diagnosis FDA Letter of Support Possibilities of a companion test in Drug Development

More information

Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego

Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego Discuss the difference between DNA Genotyping and Genome Sequencing What makes you who you

More information

Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD

Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD Platelet Refractoriness: The Basics Martin H. Bluth, MD, PhD Complete Toxicology Laboratories, LLC Objectives Define platelet refractoriness and associated conditions that may cause platelet refractoriness.

More information